Hyun-Woo Shin1, Hyunsung Choi2, Daeho So3, Young-Im Kim3, Kumsun Cho4, Hee-Joon Chung5, Kyoung-Hwa Lee6, Yang-Sook Chun7, Chung-Hyun Cho1, Gyeong Hoon Kang8, Woo Ho Kim8, Jong-Wan Park9. 1. Department of Pharmacology, Seoul National University College of Medicine, Seoul, Korea; Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. 2. Department of Pharmacology, Seoul National University College of Medicine, Seoul, Korea. 3. Department of Pharmacology, Seoul National University College of Medicine, Seoul, Korea; Department of Biomedical Science, Seoul National University College of Medicine, Seoul, Korea. 4. Department of Biomedical Science, Seoul National University College of Medicine, Seoul, Korea. 5. Seoul National University Biomedical Informatics, Seoul National University College of Medicine, Seoul, Korea. 6. Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, Korea; Department of Physiology, Seoul National University College of Medicine, Seoul, Korea. 7. Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, Korea; Department of Biomedical Science, Seoul National University College of Medicine, Seoul, Korea; Department of Physiology, Seoul National University College of Medicine, Seoul, Korea. 8. Department of Pathology, Seoul National University College of Medicine, Seoul, Korea. 9. Department of Pharmacology, Seoul National University College of Medicine, Seoul, Korea; Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; Department of Biomedical Science, Seoul National University College of Medicine, Seoul, Korea. Electronic address: parkjw@snu.ac.kr.
Abstract
BACKGROUND & AIMS: Immunoglobulin transcription factor 2 (ITF2) was believed to promote neoplastic transformation via activation of β-catenin. However, ITF2 recently was reported to suppress colon carcinogenesis. We investigated the roles of ITF2 in colorectal cancer cell lines and tumor formation and growth in mice. METHODS: Levels of ITF2, β-catenin, and c-Myc were measured in 12 human colorectal tumor samples and by immunohistochemistry. ITF2 regulation of β-catenin and T-cell factor (TCF) were analyzed using luciferase reporter, reverse-transcription quantitative polymerase chain reaction, flow cytometry, and immunoblot analyses. Mice were given subcutaneous injections of human colorectal cancer cell lines that stably express ITF2, small hairpin RNAs to reduce levels of ITF2, or control plasmids; xenograft tumor growth was assessed. Human colorectal carcinoma tissue arrays were used to associate levels of ITF2 expression and clinical outcomes. RESULTS: Levels of β-catenin, cMyc, and ITF2 were increased in areas of human colon adenomas and carcinomas, compared with nontumor areas of the same tissues. ITF2 levels were reduced and cMyc levels were increased in areas of carcinoma, compared with adenoma. In human colorectal cancer cell lines, activation of the β-catenin-TCF4 complex and expression of its target genes were regulated negatively by ITF2. ITF2 inhibited formation of the β-catenin-TCF4 complex by competing with TCF4 for β-catenin binding. Stable transgenic expression of ITF2 in human colorectal cancer cell lines reduced their proliferation and tumorigenic potential in mice, whereas small hairpin RNA knockdown of ITF2 promoted growth of xenograft tumors in mice. In an analysis of colorectal tumor tissue arrays, loss of ITF2 from colorectal tumor tissues was associated with poor outcomes of patients. A gene set enrichment analysis supported the negative correlation between the level of ITF2 and activity of the β-catenin-TCF4 complex. CONCLUSIONS: In human colorectal cancer cell lines and tissue samples, ITF2 appears to prevent activation of the β-catenin-TCF4 complex and transcription of its gene targets. Loss of ITF2 promotes the ability of colorectal cancer cells to form xenograft tumors, and is associated with tumor progression and shorter survival times of patients.
BACKGROUND & AIMS:Immunoglobulin transcription factor 2 (ITF2) was believed to promote neoplastic transformation via activation of β-catenin. However, ITF2 recently was reported to suppress colon carcinogenesis. We investigated the roles of ITF2 in colorectal cancer cell lines and tumor formation and growth in mice. METHODS: Levels of ITF2, β-catenin, and c-Myc were measured in 12 humancolorectal tumor samples and by immunohistochemistry. ITF2 regulation of β-catenin and T-cell factor (TCF) were analyzed using luciferase reporter, reverse-transcription quantitative polymerase chain reaction, flow cytometry, and immunoblot analyses. Mice were given subcutaneous injections of humancolorectal cancer cell lines that stably express ITF2, small hairpin RNAs to reduce levels of ITF2, or control plasmids; xenograft tumor growth was assessed. Humancolorectal carcinoma tissue arrays were used to associate levels of ITF2 expression and clinical outcomes. RESULTS: Levels of β-catenin, cMyc, and ITF2 were increased in areas of humancolon adenomas and carcinomas, compared with nontumor areas of the same tissues. ITF2 levels were reduced and cMyc levels were increased in areas of carcinoma, compared with adenoma. In humancolorectal cancer cell lines, activation of the β-catenin-TCF4 complex and expression of its target genes were regulated negatively by ITF2. ITF2 inhibited formation of the β-catenin-TCF4 complex by competing with TCF4 for β-catenin binding. Stable transgenic expression of ITF2 in humancolorectal cancer cell lines reduced their proliferation and tumorigenic potential in mice, whereas small hairpin RNA knockdown of ITF2 promoted growth of xenograft tumors in mice. In an analysis of colorectal tumor tissue arrays, loss of ITF2 from colorectal tumor tissues was associated with poor outcomes of patients. A gene set enrichment analysis supported the negative correlation between the level of ITF2 and activity of the β-catenin-TCF4 complex. CONCLUSIONS: In humancolorectal cancer cell lines and tissue samples, ITF2 appears to prevent activation of the β-catenin-TCF4 complex and transcription of its gene targets. Loss of ITF2 promotes the ability of colorectal cancer cells to form xenograft tumors, and is associated with tumor progression and shorter survival times of patients.
Authors: Lydia Brandl; David Horst; Enrico de Toni; Thomas Kirchner; Andreas Herbst; Frank T Kolligs Journal: Am J Cancer Res Date: 2015-06-15 Impact factor: 6.166
Authors: Zheng Chen; Mohammed Soutto; Bushra Rahman; Muhammad W Fazili; DunFa Peng; Maria Blanca Piazuelo; Heidi Chen; M Kay Washington; Yu Shyr; Wael El-Rifai Journal: Genes Chromosomes Cancer Date: 2017-04-04 Impact factor: 5.006
Authors: Olga Pernía; Ana Sastre-Perona; Carlos Rodriguez-Antolín; Alvaro García-Guede; María Palomares-Bralo; Rocío Rosas; Darío Sanchez-Cabrero; Patricia Cruz; Carmen Rodriguez; MDolores Diestro; Rubén Martín-Arenas; Verónica Pulido; Pilar Santisteban; Javier de Castro; Olga Vera; Inmaculada Ibáñez de Cáceres Journal: Cancers (Basel) Date: 2020-03-26 Impact factor: 6.639